Biodiagnóstico

biodiagnostico.com.uy

Uruguayan company dedicated to the distribution of products for IVD and Life Science. Representatives in Uruguay of Bio-Rad Laboratories, Inova Diagnostics, MP Biomedicals, IDS, Sarstedt, Diesse Diagnostics Senesse, among other leading companies in the sector.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INTENT DATA IN THE AGE OF DATA REGULATION

DECK 7 | March 23, 2020

news image

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while rem...

Read More

PHARMACY MARKET, PHARMA TECH

PRESCRYPTIVE HEALTH PARTNERS WITH LILLY ON FIRST-TO-MARKET VALUE-BASED PROGRAM TO STABILIZE INSULIN PRICING

Prescryptive Health | December 16, 2022

news image

Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market, today announced a partnership with Eli Lilly and Company on a new and first-to-market subscription model to help lower costs for people who pay for their Lilly insulin through their employer-sponsored benefits. Through a flat, per-member, per-month subscription fee, employers can offer insulin to their employees with predictable, affordable, and transparent costs. This uniq...

Read More

Practice Management

INFANT BACTERIAL THERAPEUTICS TODAY ANNOUNCES NEW PATENT PROTECTION APPROVALS IN BRAZIL AND IN HONG KONG

Infant Bacterial Therapeutics | December 28, 2021

news image

Infant Bacterial Therapeutics AB announces that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of necrotizing colitis and improvement of feeding tolerance in preterm infants. The patent covers a novel way to activate the bacteria. Corresponding patent applications are currently pending across several important future markets. This p...

Read More

Business Insights

ACULYS PHARMA AND SUSMED HAVE ENTERED INTO A CONTRACT TO CONDUCT THE WORLD'S FIRST CLINICAL TRIAL UTILIZING BLOCKCHAIN TECHNOLOGY

Aculys Pharma, Inc. | July 13, 2022

news image

Aculys Pharma, Inc. a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, has entered into a contract with SUSMED, Inc., a company that promotes digital medicine to conduct the world's first1 corporate-sponsored clinical trial using blockchain technology. The clinical trial utilizing this blockchain technology, provided by SUSMED, will be conducted in collaboration with CMIC Co., Ltd., a pioneer in drug development suppo...

Read More
news image

INTENT DATA IN THE AGE OF DATA REGULATION

DECK 7 | March 23, 2020

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while rem...

Read More
news image

PHARMACY MARKET, PHARMA TECH

PRESCRYPTIVE HEALTH PARTNERS WITH LILLY ON FIRST-TO-MARKET VALUE-BASED PROGRAM TO STABILIZE INSULIN PRICING

Prescryptive Health | December 16, 2022

Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market, today announced a partnership with Eli Lilly and Company on a new and first-to-market subscription model to help lower costs for people who pay for their Lilly insulin through their employer-sponsored benefits. Through a flat, per-member, per-month subscription fee, employers can offer insulin to their employees with predictable, affordable, and transparent costs. This uniq...

Read More
news image

Practice Management

INFANT BACTERIAL THERAPEUTICS TODAY ANNOUNCES NEW PATENT PROTECTION APPROVALS IN BRAZIL AND IN HONG KONG

Infant Bacterial Therapeutics | December 28, 2021

Infant Bacterial Therapeutics AB announces that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of necrotizing colitis and improvement of feeding tolerance in preterm infants. The patent covers a novel way to activate the bacteria. Corresponding patent applications are currently pending across several important future markets. This p...

Read More
news image

Business Insights

ACULYS PHARMA AND SUSMED HAVE ENTERED INTO A CONTRACT TO CONDUCT THE WORLD'S FIRST CLINICAL TRIAL UTILIZING BLOCKCHAIN TECHNOLOGY

Aculys Pharma, Inc. | July 13, 2022

Aculys Pharma, Inc. a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, has entered into a contract with SUSMED, Inc., a company that promotes digital medicine to conduct the world's first1 corporate-sponsored clinical trial using blockchain technology. The clinical trial utilizing this blockchain technology, provided by SUSMED, will be conducted in collaboration with CMIC Co., Ltd., a pioneer in drug development suppo...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us